Compare Stocks: SRRK, BNTX, MRNA, and VTRS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$90.58 -2.4%	$91.48	$79.52 ▼ $124.00	$22.91B	1.27	770,553 shs	710,905 shs
MRNA Moderna	$54.82 -5.4%	$59.37	$22.28 ▼ $85.60	$21.75B	0.91	6.17 million shs	7.76 million shs
SRRK Scholar Rock	$47.29 -3.5%	$50.11	$27.07 ▼ $58.49	$5.67B	0.69	1.06 million shs	786,740 shs
VTRS Viatris	$17.56 -1.1%	$16.46	$8.63 ▼ $18.07	$20.45B	0.9	9.31 million shs	15.57 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	0.00%	+1.40%	-7.14%	-7.14%	-17.69%
MRNA Moderna	0.00%	+1.39%	-31.27%	+20.83%	+70.51%
SRRK Scholar Rock	0.00%	-0.80%	-13.83%	+1.98%	+25.01%
VTRS Viatris	0.00%	+1.86%	+5.15%	+16.76%	+95.11%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$90.58 -2.4%	$91.48	$79.52 ▼ $124.00	$22.91B	1.27	770,553 shs	710,905 shs
MRNA Moderna	$54.82 -5.4%	$59.37	$22.28 ▼ $85.60	$21.75B	0.91	6.17 million shs	7.76 million shs
SRRK Scholar Rock	$47.29 -3.5%	$50.11	$27.07 ▼ $58.49	$5.67B	0.69	1.06 million shs	786,740 shs
VTRS Viatris	$17.56 -1.1%	$16.46	$8.63 ▼ $18.07	$20.45B	0.9	9.31 million shs	15.57 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	0.00%	+1.40%	-7.14%	-7.14%	-17.69%
MRNA Moderna	0.00%	+1.39%	-31.27%	+20.83%	+70.51%
SRRK Scholar Rock	0.00%	-0.80%	-13.83%	+1.98%	+25.01%
VTRS Viatris	0.00%	+1.86%	+5.15%	+16.76%	+95.11%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.74	Moderate Buy	$129.13	42.55% Upside
MRNA Moderna	1.82	Reduce	$40.00	-27.03% Downside
SRRK Scholar Rock	3.12	Buy	$56.21	18.87% Upside
VTRS Viatris	2.57	Moderate Buy	$17.50	-0.34% Downside

Current Analyst Ratings Breakdown

Latest SRRK, BNTX, MRNA, and VTRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/23/2026	VTRS Viatris	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
7/21/2026	MRNA Moderna	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$49.00 ➝ $67.00
7/21/2026	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$58.00
7/20/2026	MRNA Moderna	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underperform	$25.00
7/17/2026	SRRK Scholar Rock	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/8/2026	MRNA Moderna	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$33.00 ➝ $39.00
7/8/2026	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$126.00 ➝ $119.00
7/7/2026	VTRS Viatris	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
7/7/2026	MRNA Moderna	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$38.00 ➝ $45.00
7/7/2026	MRNA Moderna	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Underperform	$34.00 ➝ $38.00
7/6/2026	BNTX BioNTech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$3.25B	7.06	$1.34 per share	67.84	$96.59 per share	0.94
MRNA Moderna	$1.94B	11.19	N/A	N/A	$22.14 per share	2.48
SRRK Scholar Rock	N/A	N/A	N/A	N/A	$2.41 per share	N/A
VTRS Viatris	$14.30B	1.43	$7.38 per share	2.38	$12.77 per share	1.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$1.29B	-$5.88	N/A	N/A	N/A	-44.39%	-5.30%	-4.62%	8/4/2026 (Estimated)
MRNA Moderna	-$2.82B	-$8.15	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	N/A
SRRK Scholar Rock	-$377.94M	-$3.59	N/A	N/A	N/A	N/A	-163.52%	-96.67%	8/6/2026 (Confirmed)
VTRS Viatris	-$3.51B	-$0.26	N/A	6.58	1.60	-2.04%	19.04%	7.62%	8/6/2026 (Estimated)

Latest SRRK, BNTX, MRNA, and VTRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	SRRK Scholar Rock	-$0.8405	N/A	N/A	N/A	$3.33 million	N/A
8/6/2026	Q2 2026	VTRS Viatris	$0.6010	N/A	N/A	N/A	$3.68 billion	N/A
8/4/2026	Q2 2026	BNTX BioNTech	-$2.3999	N/A	N/A	N/A	$183.75 million	N/A
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million
5/7/2026	Q1 2026	SRRK Scholar Rock	-$0.82	-$0.83	-$0.01	-$0.83	$5.00 million	N/A
5/7/2026	Q1 2026	VTRS Viatris	$0.52	$0.59	+$0.07	$0.15	$3.36 billion	$3.52 billion
5/4/2026	Q1 2026	BNTX BioNTech	-$2.52	-$2.2570	+$0.2630	-$2.43	$207.42 million	$136.71 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A
VTRS Viatris	$0.48	2.73%	N/A	N/A	N/A

Latest SRRK, BNTX, MRNA, and VTRS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/4/2026	VTRS Viatris	quarterly	$0.12	2.88%	5/22/2026	5/22/2026	6/17/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	8.80	8.74
MRNA Moderna	0.09	2.29	2.18
SRRK Scholar Rock	0.71	8.64	8.64
VTRS Viatris	0.85	1.60	1.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
MRNA Moderna	75.33%
SRRK Scholar Rock	91.08%
VTRS Viatris	79.88%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
MRNA Moderna	10.80%
SRRK Scholar Rock	10.30%
VTRS Viatris	0.28%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
MRNA Moderna	4,700	396.79 million	353.93 million	Optionable
SRRK Scholar Rock	140	119.83 million	107.49 million	Optionable
VTRS Viatris	30,000	1.16 billion	1.16 billion	Optionable

SRRK, BNTX, MRNA, and VTRS Headlines

Recent News About These Companies

Viatris (VTRS) Wins FDA Approval For Gwyn Lo Contraceptive Patch

August 2 at 6:58 PM | finance.yahoo.com

Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run

July 31 at 5:15 PM | seekingalpha.com

Viatris (VTRS) Q2 Earnings Preview: What's in the Cards?

July 30 at 11:02 AM | zacks.com

J.P. Morgan Sticks to Its Hold Rating for Viatris (VTRS)

July 29, 2026 | theglobeandmail.com

Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch

July 29, 2026 | prnewswire.com

Generic pharmaceuticals stocks Q1 highlights: Viatris (NASDAQ:VTRS)

July 28, 2026 | msn.com

UBS Reaffirms Their Buy Rating on Viatris (VTRS)

July 23, 2026 | theglobeandmail.com

Viatris’ quarterly earnings preview: What you need to know

July 23, 2026 | msn.com

Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply

July 22, 2026 | cnbc.com

Bank of America Securities Keeps Their Sell Rating on Viatris (VTRS)

July 11, 2026 | theglobeandmail.com

Why Viatris (VTRS) is a Top Value Stock for the Long-Term

July 10, 2026 | zacks.com

VTRS or DHR: Which Is the Better Value Stock Right Now?

July 9, 2026 | zacks.com

Should Value Investors Buy Viatris (VTRS) Stock?

July 9, 2026 | zacks.com

3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now

July 7, 2026 | 247wallst.com

Should Viatris’ Japan IgA Nephropathy Win and New Loan Shape VTRS Investors’ Next Move?

July 6, 2026 | finance.yahoo.com

Viatris (VTRS) Secures Loan Amid Positive Phase 3 Results

July 5, 2026 | insidermonkey.com

Viatris (VTRS) Secures Loan Amid Positive Phase 3 Results

July 5, 2026 | finance.yahoo.com

Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now

July 5, 2026 | insidermonkey.com

Viatris Inc.

July 5, 2026 | marketwatch.com

Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now

July 5, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SRRK, BNTX, MRNA, and VTRS Company Descriptions

BioNTech NASDAQ:BNTX

$90.58 -2.27 (-2.44%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$90.16 -0.42 (-0.46%)

As of 07/31/2026 07:57 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Moderna NASDAQ:MRNA

$54.82 -3.10 (-5.35%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$54.66 -0.16 (-0.29%)

As of 07/31/2026 07:57 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Scholar Rock NASDAQ:SRRK

$47.29 -1.70 (-3.47%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$47.30 +0.01 (+0.01%)

As of 07/31/2026 07:34 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Viatris NASDAQ:VTRS

$17.56 -0.20 (-1.13%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$17.24 -0.31 (-1.79%)

As of 07/31/2026 07:55 PM Eastern

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SRRK, BNTX, MRNA, and VTRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SRRK, BNTX, MRNA, and VTRS Earnings

Compare Dividends

Latest SRRK, BNTX, MRNA, and VTRS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SRRK, BNTX, MRNA, and VTRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SRRK, BNTX, MRNA, and VTRS Company Descriptions

BioNTech NASDAQ:BNTX

Moderna NASDAQ:MRNA

Scholar Rock NASDAQ:SRRK

Viatris NASDAQ:VTRS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools